Valuation: Keymed Biosciences Inc.

Market Cap 19.58B 22.79B 2.91B 2.51B 2.36B 2.15B 4.03B 278B 4.09B 27.64B 10.81B 139B 10.91B 10.67B 463B P/E 2026 *
25.7x
P/E 2027 * 1,347x
Enterprise Value 18.33B 21.34B 2.72B 2.35B 2.21B 2.01B 3.77B 260B 3.83B 25.88B 10.13B 130B 10.21B 9.99B 434B EV / Sales 2026 *
8.1x
EV / Sales 2027 * 8.56x
Free-Float
74.84%
Yield 2026 *
-
Yield 2027 * -
1 day-1.02%
1 week-5.50%
Current month+5.81%
1 month-10.01%
3 months+17.11%
6 months+43.24%
Current year+44.71%
1 week 75.15
Extreme 75.15
84.8
1 month 71.15
Extreme 71.15
88.8
Current year 44.66
Extreme 44.66
89.75
1 year 44.66
Extreme 44.66
89.75
3 years 26.6
Extreme 26.6
89.75
5 years 16.9
Extreme 16.9
89.75
10 years 16.9
Extreme 16.9
89.75
Manager TitleAgeSince
Chief Executive Officer 52 2018-04-22
Corporate Officer/Principal 61 2021-03-02
Corporate Secretary - 2022-03-28
Director TitleAgeSince
Chairman 52 2018-04-22
Director/Board Member 61 2021-03-02
Director/Board Member 52 2018-06-20
Date Insider Type Main position Quantity % Market Cap.
6/13/25
Moonshot Holdings Ltd.
OtherCompany 21,600,000 7.7216%
6/11/25
Moonshot Holdings Ltd.
OtherCompany 18,800,000 6.7206%
9/15/23
Moonshot Holdings Ltd.
OtherCompany 114,500 0.0409%
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-5.50%+4.67%+65.63% 2.93B
+4.80%+7.80%+70.64%+114.21% 70.07B
+17.12%+12.05%+54.42%+86.20% 52.87B
+3.70%-2.12%+0.41%+469.55% 27.02B
+2.26%+0.65%+49.19%+10.30% 23.61B
-1.60%-2.21%-19.31%-15.15% 23.38B
-6.00%+13.71%+244.39%+443.26% 19.43B
+3.80%+5.25%+40.50%-16.41% 18.75B
+0.38%-3.15%+20.39%+589.77% 15.85B
+2.11%-3.24%+36.57%+145.40% 12.7B
Average +2.55%-2.32%+50.19%+189.28% 26.66B
Weighted average by Cap. +5.03%-1.18%+55.72%+168.15%

Financials

2026 *2027 *
Net sales 2.26B 2.63B 336M 290M 272M 248M 466M 32.1B 473M 3.19B 1.25B 16.07B 1.26B 1.23B 53.54B 2.13B 2.47B 315M 272M 256M 233M 438M 30.15B 444M 3B 1.17B 15.09B 1.18B 1.16B 50.28B
Net income 600M 699M 89.09M 76.95M 72.25M 65.78M 124M 8.52B 125M 847M 332M 4.26B 334M 327M 14.2B -18.88M -21.97M -2.8M -2.42M -2.27M -2.07M -3.89M -268M -3.94M -26.64M -10.42M -134M -10.52M -10.29M -447M
Net Debt -1.25B -1.45B -185M -160M -150M -137M -257M -17.68B -260M -1.76B -688M -8.85B -694M -679M -29.48B -1.39B -1.62B -206M -178M -167M -152M -286M -19.7B -290M -1.96B -767M -9.86B -774M -757M -32.85B
Logo Keymed Biosciences Inc.
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
1,625
Date Price Change Volume
26-08-17 HK$77.35 -1.02% 1,487,466
26-08-14 HK$78.15 -1.26% 1,168,500
26-08-13 HK$79.15 -2.04% 2,295,000
26-08-12 HK$80.80 -2.24% 1,441,500
26-08-11 HK$82.65 +0.92% 3,330,608
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
66.46CNY
Average target price
83.81CNY
Spread / Average Target
+26.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2162 Stock